Key points are not available for this paper at this time.
Targeted protein degradation is becoming more and more important in the field of drug development. Compared with proteasomal-based degraders, lysosomal-based degraders have a broader target spectrum of targets, which have been demonstrated to have great potential, especially in degrading undruggable proteins. Recently, we developed a programmable and facile screening PROTAC development platform based on peptide self-assembly termed split-and-mix PROTAC (SM-PROTAC). In this study, we applied this technology for the development of lysosome-based degraders, named a split-and-mix chaperone-mediated autophagy-based degrader (SM-CMAD). We successfully demonstrated SM-CMAD as a universal platform by degrading several targets, including ERα, AR, MEK1/2, and BCR-ABL. Different from other lysosomal-based degraders, SM-CMAD was capable of facile screening with programmable ligand ratios. We believe that our work will promote the development of other multifunctional molecules and clinical translation for lysosomal-based degraders.
Building similarity graph...
Analyzing shared references across papers
Loading...
Jinpeng Wang
Yuncheng University
Yuechen Wang
Shanxi Agricultural University
Fenfang Yang
Shenzhen Bay Laboratory
ACS Chemical Biology
Peking University
Shenzhen Second People's Hospital
Shenzhen Bay Laboratory
Building similarity graph...
Analyzing shared references across papers
Loading...
Wang et al. (Thu,) studied this question.
synapsesocial.com/papers/68e6d971b6db64358765572b — DOI: https://doi.org/10.1021/acschembio.4c00092
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: